As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

As­traZeneca is part­ner­ing with Quell Ther­a­peu­tics to de­vel­op reg­u­la­to­ry T cell ther­a­pies for type 1 di­a­betes and in­flam­ma­to­ry bow­el dis­ease, join­ing the grow­ing move­ment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER